68126 Federal Register / Vol. 88, No. 190 / Tuesday, October 3, 2023 / Notices 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6710B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ms. Lisa Neal, Committee 

Management Officer, Committee 

Management Branch, Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development, NIH, 6701B, 

Rockledge Drive, Room 2208, Bethesda, MD 

20892, (301) 204–1830, lisa.neal@nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: https:// 

www.nichd.nih.gov/about/advisory/council, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 27, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21776 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; HIGH IMPACT 

NIDDK RC2 APPLICATIONS. 

Date: November 3, 2023. 

Time: 3:30 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ryan G. Morris, Ph.D., 

Scientific Review Officer, NIDDK/Scientific 

Review Branch, National Institutes of Health, 

6707 Democracy Boulevard, Room 7015, 

Bethesda, MD 20892–2542, (301) 594–4721, 

ryan.morris@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 27, 2023. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21771 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Avenir 

Award Program for Chemistry and 

Pharmacology of Substance Use Disorders. 

Date: January 10, 2024. 

Time: 9:45 a.m. to 5:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Marisa Srivareerat, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 435–1258, 

marisa.srivareerat@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: September 28, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21815 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary, Interagency 

Pain Research Coordinating 

Committee Call for Committee 

Membership Nominations 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) (Department) 

has created the Interagency Pain 

Research Coordinating Committee 

(IPRCC) and is seeking nominations for 

this committee. 

DATES: Nominations are due by 5 p.m. 

ET on November 01, 2023. 

ADDRESSES: Nominations must be 

submitted through the webform on the 

IPRCC website: https://

www.surveymonkey.com/r/IPRCCnomination-form. 

FOR FURTHER INFORMATION CONTACT: 

Linda Porter, porterl@ninds.nih.gov or 

301–451–4460. 

SUPPLEMENTARY INFORMATION: As 

specified in Public Law 111–148 

(‘‘Patient Protection and Affordable Care 

Act’’) the Committee will: 

(A) develop a summary of advances in 

pain care research supported or 

conducted by the Federal agencies 

relevant to the diagnosis, prevention, 

and treatment of pain and diseases and 

disorders associated with pain; 

(B) identify critical gaps in basic and 

clinical research on the symptoms and 

causes of pain; 

(C) make recommendations to ensure 

that the activities of the National 

Institutes of Health and other Federal 

agencies are free of unnecessary 

duplication of effort; 

(D) make recommendations on how 

best to disseminate information on pain 

care; and (e) make recommendations on 

how to expand partnerships between 

public entities and private entities to 

expand collaborative, cross-cutting 

research. 

Membership on the committee will 

include six (6) non-Federal members 

from among scientists, physicians, and 

other health professionals and six (6) 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 190 / Tuesday, October 3, 2023 / Notices 68127 

non-Federal members of the general 

public who are representatives of 

leading research, advocacy, and service 

organizations for individuals with painrelated conditions. Members will serve 

overlapping three year terms. It is 

anticipated that the committee will meet 

at least once a year. 

The Department strives to ensure that 

the membership of HHS Federal 

advisory committees is fairly balanced 

in terms of points of view represented 

and the committee’s function. Every 

effort is made to ensure that the views 

of diverse ethnic and racial groups and 

people with disabilities are represented 

on HHS Federal advisory committees, 

and the Department therefore, 

encourages nominations of qualified 

candidates from these groups. The 

Department also encourages geographic 

diversity in the composition of the 

Committee. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. 

The Department is soliciting 

nominations for two non-federal 

members from among scientists, 

physicians, and other health 

professionals and for two non-federal 

members of the general public who 

represent a leading research, advocacy, 

or service organization for people with 

pain-related conditions. These 

candidates will be considered to fill 

positions opened through completion of 

current member terms. Nominations are 

due by 5:00 p.m. ET on November 01, 

2023, using the IPRCC nomination 

webform: https://

www.surveymonkey.com/r/IPRCCnomination-form. 

More information about the IPRCC is 

available at https://www.iprcc.nih.gov/. 

Dated: September 27, 2023. 

Walter J. Koroshetz, 

Director, National Institute of Neurological 

Disorders and Stroke, National Institutes of 

Health. 

[FR Doc. 2023–21761 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Implementation Cooperative Agreement (U01 

Clinical Trial Required). 

Date: October 30, 2023. 

Time: 1:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E71, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Ann Marie M. Brighenti, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E71, 

Rockville, MD 20852, 301–761–3100, 

AnnMarie.Cruz@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 26, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21743 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grants (R34 Clinical Trial Not 

Allowed) and NIAID SBIR Phase II Clinical 

Trial Implementation Cooperative Agreement 

(U44 Clinical Trial Required). 

Date: December 5, 2023. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E71, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Samita Andreansky, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E71, Rockville, MD 

20852, 240–669–2915, samita.andreansky@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 27, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21770 Filed 10–2–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Catalyze Enabling Technologies. 

Date: December 4, 2023. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1